Injection, reslizumab, 1mg
Products billed under this code include Cinqair.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Cinqair.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Cinqair | Teva Respiratory, LLC | 59310-0610-31 | 100 | $1,190.70 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $11.907 | +$0.178 | 1 MG | Injection, reslizumab, 1mg | v1, posted September 17, 2026 |
| 3Q26 | $11.729 | +$0.197 | 1 MG | Injection, reslizumab, 1mg | v1, posted September 15, 2026 |
| 2Q26 | $11.532 | +$0.398 | 1 MG | Injection, reslizumab, 1mg | v1, posted September 15, 2026 |
| 1Q26 | $11.134 | +$0.183 | 1 MG | Injection, reslizumab, 1mg | v1, posted September 15, 2026 |
| 4Q25 | $10.951 | +$0.376 | 1 MG | Injection, reslizumab, 1mg | v1, posted September 8, 2026 |
| 3Q25 | $10.575 | +$0.081 | 1 MG | Injection, reslizumab, 1mg | v1, posted March 10, 2026 |
| 2Q25 | $10.494 | +$0.175 | 1 MG | Injection, reslizumab, 1mg | v1, posted March 10, 2026 |
| 1Q25 | $10.319 | +$0.008 | 1 MG | Injection, reslizumab, 1mg | v1, posted December 19, 2025 |
| 4Q24 | $10.311 | +$0.225 | 1 MG | Injection, reslizumab, 1mg | v1, posted June 11, 2025 |
| 3Q24 | $10.086 | −$0.139 | 1 MG | Injection, reslizumab, 1mg | v1, posted June 11, 2025 |
| 2Q24 | $10.225 | +$0.057 | 1 MG | Injection, reslizumab, 1mg | v1, posted March 11, 2025 |
| 1Q24 | $10.168 | −$0.133 | 1 MG | Injection, reslizumab, 1mg | v1, posted December 19, 2024 |
| 4Q23 | $10.301 | +$0.103 | 1 MG | Injection, reslizumab, 1mg | v1, posted October 10, 2024 |
| 3Q23 | $10.198 | +$0.043 | 1 MG | Injection, reslizumab, 1mg | v1, posted June 5, 2024 |
| 2Q23 | $10.155 | +$0.055 | 1 MG | Injection, reslizumab, 1mg | v1, posted February 23, 2024 |
| 1Q23 | $10.10 | −$0.006 | 1 MG | Injection, reslizumab, 1mg | v1, posted December 6, 2023 |
| 4Q22 | $10.106 | +$0.161 | 1 MG | Injection, reslizumab, 1mg | v1, posted June 22, 2023 |
| 3Q22 | $9.945 | −$0.287 | 1 MG | Injection, reslizumab, 1mg | v1, posted June 9, 2023 |
| 2Q22 | $10.232 | +$0.103 | 1 MG | Injection, reslizumab, 1mg | v1, posted December 14, 2022 |
| 1Q22 | $10.129 | +$0.015 | 1 MG | Injection, reslizumab, 1mg | v1, posted June 8, 2022 |
| 4Q21 | $10.114 | +$0.158 | 1 MG | Injection, reslizumab, 1mg | v1, posted June 2, 2022 |
| 3Q21 | $9.956 | −$0.012 | 1 MG | Injection, reslizumab, 1mg | v1, posted June 2, 2022 |
| 2Q21 | $9.968 | +$0.214 | 1 MG | Injection, reslizumab, 1mg | v1, posted March 1, 2022 |
| 1Q21 | $9.754 | – | 1 MG | Injection, reslizumab, 1mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.